Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

NICE has produced a resource impact template that incorporates the following technology appraisal guidance for migraine:

• Atogepant for preventing migraine (2024) NICE technology appraisal guidance 973
• Rimegepant for treating migraine (2023) NICE technology appraisal guidance 919
• Rimegepant for preventing migraine (2023) NICE technology appraisal guidance 906
• Eptinezumab for preventing migraine (2023) NICE technology appraisal guidance 871
• Fremanezumab for preventing migraine (2022) NICE technology appraisal guidance 764
• Erenumab for preventing migraine (2021) NICE technology appraisal guidance 682
• Galcanezumab for preventing migraine (2020) NICE technology appraisal guidance 659
• Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (2012) NICE technology appraisal guidance 260